Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity?
about
Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorderPreclinical antiepileptic actions of selective serotonin reuptake inhibitors--implications for clinical trial designGender differences in patients with dizziness and unsteadiness regarding self-perceived disability, anxiety, depression, and its associations.Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments.First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic β-cell mass.Clinical pharmacology in sleep medicine.Mammalian sleep genetics.Extensions to In Silico Bioactivity Predictions Using Pathway Annotations and Differential Pharmacology Analysis: Application to Xenopus laevis Phenotypic Readouts.Oral health related quality of life of Greek adolescents: a cross-sectional study.The wake-promoting transmitter histamine preferentially enhances α-4 subunit-containing GABAA receptors.Inhibition of hippocampal excitability by citalopram.DizzyReg: the prospective patient registry of the German Center for Vertigo and Balance Disorders.Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS1dE9 Mice.Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects
P2860
Q26823991-51F85F54-593E-40D2-B4F7-CF12FED19CD4Q26850811-8973AA54-4B5C-41C2-A733-E824BFE52AACQ34205166-AF2A24FC-7265-4813-9E9C-4390CDAD8A09Q35547596-377824E8-96A2-4A4C-994D-4D3B6689DFB2Q35947964-B24D889D-E053-4A7E-844A-149B5D1BB440Q36417984-D3CF2EDC-29ED-48CB-951E-036F7E9B16CFQ38043400-53E05A0C-5872-483E-BBEA-D1A9FBD67C70Q38915525-FEEF8234-6EE4-4A36-A0F5-C56FC9A58C0CQ39985687-0997867A-E555-417A-A1C3-36A4D2981EBFQ42094690-CB867DB4-BFA7-48B1-BC1E-5C5924107082Q43647176-D8B379ED-BE0B-4AE3-B4F5-253748EA3829Q48151921-25D9BAC6-074E-49B1-A94D-894834E61C51Q50541378-7DFC115D-A490-49F7-A386-5B175D41FCFDQ54152494-FBC25B81-5A16-40F1-A65B-D3AB939E5C12
P2860
Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity?
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@ast
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@en
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@nl
type
label
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@ast
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@en
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@nl
prefLabel
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@ast
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@en
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@nl
P2860
P356
P1433
P1476
Targeting ligand-gated ion cha ...... an obstacle or an opportunity?
@en
P2093
Emmanuel J Botzolakis
Matt T Bianchi
P2860
P2888
P356
10.1186/1471-2210-10-3
P577
2010-03-02T00:00:00Z
P5875
P6179
1046555767